**Name of journal: World Journal of Clinical Oncology**

**ESPS Manuscript NO: 8731**

**Columns: TOPIC HIGHLIGHT**

WJCO 5th Anniversary Special Issues (2): Breast cancer

Epithelial-mesenchymal transition transcription factors and miRNAs: “Plastic surgeons” of breast cancer

Moyret-Lalle C *et al*. “Plastic surgeons” of breast cancer

Caroline Moyret-Lalle, Emmanuelle Ruiz, Alain Puisieux

**Caroline Moyret-Lalle, Emmanuelle Ruiz, Alain Puisieux,** INSERM UMR-S1052, Centre de Recherche en Cancérologie de Lyon, 69008 Lyon, France

**Caroline Moyret-Lalle, Emmanuelle Ruiz, Alain Puisieux,** CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69008 Lyon, France

**Caroline Moyret-Lalle, Emmanuelle Ruiz, Alain Puisieux,** Laboratoire d’EXcellence DEVweCAN, INSERM UMR-S1052 CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69008 Lyon, France

**Caroline Moyret-Lalle, Emmanuelle Ruiz, Alain Puisieux,** INSERM UMR-S1052 CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, 69008 Lyon, France

**Author contributions:** Moyret-Lalle C and Ruiz E wrote the manuscript and designed the figures; and Puisieux A coordinated and was involved in editing the manuscript.

**Supported by** The Ligue Nationale contre le Cancer, to Puisieux A

**Correspondence to: Caroline Moyret-Lalle, PhD,** Laboratoire d’EXcellence DEVweCAN, INSERM UMR-S1052 CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 43 Boulevard du 11 Novembre 1918, 69008 Lyon, France**.** caroline.moyret-lalle@lyon.unicancer.fr

**Telephone:** +33-4-78782710 **Fax:** +33-4-78782020

**Received:** January 3, 2014 **Revised:** June 13, 2014

**Accepted:** June 27, 2014

**Published online:**

**Abstract**

Growing evidence suggests that breast cancer cell plasticity arises due to a partial reactivation of epithelial-mesenchymal transition (EMT) programs in order to give cells pluripotency, leading to a stemness-like phenotype. A complete EMT would be a dead end program that would render cells unable to fully metastasize to distant organs. Evoking the EMT-mesenchymal-to-epithelial transition (MET) cascade promotes successful colonization of distal target tissues. It is unlikely that direct reprogramming or trans-differentiation without passing through a pluripotent stage would be the preferred mechanism during tumor progression. This review focuses on key EMT transcriptional regulators, EMT-transcription factors involved in EMT (TFs) and the miRNA pathway, which are deregulated in breast cancer, and discusses their implications in cancer cell plasticity. Cross-regulation between EMT-TFs and miRNAs, where miRNAs act as co-repressors or co-activators, appears to be a pivotal mechanism for breast cancer cells to acquire a stem cell-like state, which is implicated both in breast metastases and tumor recurrence. As a master regulator of miRNA biogenesis, the ribonuclease type III endonuclease Dicer plays a central role in EMT-TFs/miRNAs regulating networks. All these EMT-MET key regulators represent valuable new prognostic and predictive markers for breast cancer as well as promising new targets for drug-resistant breast cancers.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Embryonic transcription factors; Epithelial to mesenchymal transition; Breast cancer; MicroRNAs; Dicer; Feedback loop

**Core tip:** Epithelial-mesenchymal transition (EMT) and the reverse mesenchymal–epithelial transition (MET) are both involved in breast cancer plasticity. Embryonic transcription factors and miRNAs are key players regulating the balance between these two processes allowing cells that underwent EMT to transiently re-acquire epithelial phenotype. Here we highlighted the complex transcription factors/miRNAs regulation networks involved in EMT-MET during breast cancer progression and the central role played by Dicer, the key enzyme of miRNAs processing, in EMT process. These key regulators of EMT-MET may represent predictive markers and potential therapeutic targets for breast cancers.

Moyret-Lalle C, Ruiz E, Puisieux A. Epithelial-mesenchymal transition transcription factors and miRNAs: “Plastic surgeons” of breast cancer. *World J Clin Oncol* 2014; In press

**EMT AND MET REPROGRAMMING DURING BREAST CANCER PROGRESSION**

During embryonic development, a complex organism is formed from a single starting cell. Growth and differentiation are driven by large transcriptional changes, directed by the expression and activity of transcription factors (TFs). Cancer is often suggested to imperfectly resemble the development process by re-expressing certain embryonic TFs. Links between normal embryonic development and cancer biology have been postulated, but no defined genetic/epigenetic basis has been established. During normal development, cells divide, align themselves, and specialize to form discrete tissues and organs. For the body to develop properly, cells must coordinate their migratory patterns and the process by which they differentiate or evolve from less-specialized cells into more-specialized cell types. A lack of such coordination leads to disordered development and, in some cases, cancer.

The mammary gland is an organ that undergoes distinct and complex developmental stages after birth. Post-natally, mammary ducts elongate into the mammary fat pad. Terminal end buds, the highly proliferative structures found at the tips of the invading ducts, expand and increase greatly after birth. By puberty, the mammary ducts have invaded to the end of the mammary fat pad. At this point, the terminal end buds become less proliferative and decrease in size. Side branches form from the primary ducts and begin to fill the mammary fat pad. Ductal development decreases with the arrival of [sexual maturity](http://en.wikipedia.org/wiki/Sexual_maturity) and undergoes [estrous cycles](http://en.wikipedia.org/wiki/Estrous_cycle). As a result of estrous cycling, the mammary gland undergoes dynamic changes where cells proliferate and then regress. During each estrus cycle, the density of ductal branches and alveolar buds increases. During pregnancy, the alveolar buds formed on the ductal tree giverise to large, lobulo-alveolar differentiated structures capable of milk production. Understanding how the mammary tissue develops and functions is of great importance in determining how its control mechanisms break down in breast cancer. The leucine-rich repeat containing G protein-coupled receptor 4 (Lgr4) has been implicated in mammary development and stem cell activity, with *Lgr4-/-* mice showing delayed ductal development, fewer terminal end buds, and decreased side-branching mediated by the Wnt/-catenin/Lef1 pathway and Sox2[1]. An article from the Breakthrough Breast Cancer Research Centre has recently compared an embryonic mammary epithelial signature with *Brca1*-deficient mouse mammary tumors and human breast cancer signatures. Specific subsets of embryonic mammary genes were found over-expressed both in mouse *Brca1-/-* tumors and in human basal-like cancers[2]. Reactivation of a small network of embryonic mammary programs within differentiated tumor cells may elicit cell behavior associated with a stem-like, highly plastic state. The EMT-mesenchymal-to-epithelial transition (MET) cascade, although an intrinsic part of normal developmental processes during organogenesis, is also recognized as a critical event for metastasis of carcinomas[3; 4]. EMT allows tumor cells to de-differentiate and to acquire motility and invasive properties in order to spread into distant organs, and the MET program then reboots an epithelial program to establish new tumors at the sites of dissemination[5]. It is not entirely known how and when EMT and MET programs, and the genes associated with these processes, are coordinated. The hallmark of EMT is the loss of adherent junctions through loss of E-cadherin (CDH1) expression. E-cadherin repressors fall into two groups, direct or indirect regulators, depending on whether or not they bind the *CDH1* promoter.

**EMT INDUCERS**

The powerful direct repressors of *CDH1*, playing a major role in EMT, originate from three distinct families: The Snail family comprises three members, Snai1, 2 and 3 (also termed Snail, Slug and Smuc), the Zeb family (Zeb1/2), which are zinc-finger transcription factors that recognize a consensus E-box type element, and the b-HLH family (TWIST1/2) which also bind to a consensus E-Box sequence, as homo- or heterodimers. These factors also repress the transcription of several other junctional proteins, including claudins and des­mosomes. The other group of *CDH1* repressors (indirect regulators) comprises FoxC2, Goosecoid, TCF4, paired mesoderm homeobox protein 1 (PRRX1), and some Sox family members. FoxC2 is a winged helix/Forkhead domain transcription factor, which lies downstream of Twist, Snail and Goosecoid, and affects E-cadherin expression by promoting its cytoplasmic localization. They increase the invasiveness of epithelial cells (Table 1). The third member of the Snail family, (Smuc) does not play a major role during EMT, while Zeb1 is a strong motility driver. The Snail, Zeb and TWIST families operate within a complex regulatory network where they activate or repress each other. EMT inducers, such as EMT-TFs (TWIST1, Snail, Slug, and Zeb1), can also confer ‘stemness’ as demonstrated in several studies, where the induction of EMT enhances self-renewal and the acquisition of CSC (Cancer Stem Cell) characteristics[6-8] (Table 1). In contrast, several studies show that tumor cells with an epithelial phenotype survive in the circulation and form distant metastases[9-12]. It has been demonstrated that the mesenchymal phenotype does not facilitate metastatic progression; rather, most cancers invade and travel through lymphatic and blood vessels via cohesive epithelial migration, and do not undergo EMT-MET[13]. Interestingly, Zvelebil *et al*[2] showed that enrichment for the mammary mesenchymal gene signature (TGFI, TWIST2, ZEB2) was correlated with large tumor size, but no significant association with overall survival was observed in patients whose breast cancers showed activation of the embryonic mesenchymal signature. Four transcription factors (Bcl11a, Grhl3, Prox1, Sox11) activated in *Brca1-/-* mouse tumors and basal-like human breast cancers were confirmed to be embryonic-enriched and highly expressed by some tumors. Increasingly, evidence points towards the transient involvement of an activated EMT program in the invasive front of tumors rather than in dissemination of cancer cells. The mesenchymal transcriptomic program is found associated with metaplastic breast carcinoma (MBC), a rare tumor with a carcinosarcoma-like aspect, with a larger tumor size, accounting for <1% of all breast cancers. Histologic subtypes identified were chondroid (24%), spindle (20%), sarcomatoid (16%), squamous (11%) and mixed (29%), with the origin of the “mixed” subtype hypothesized to be from the “differentiation” of immature breast glandular epithelial cells into non-glandular mesenchymal tissue. In prostate cancer cell lines, subpopulations with a strong epithelial gene program were enriched in highly metastatic tumor-initiating cells (TICs), whereas mesenchymal subpopulations showed reduced TIC[12]. Are epithelial cancer cells expressing EMT-TFs without experiencing a full EMT program the most prominent to metastasize? The answer is no for some factors, as it was recently shown that TWIST1 down-regulation and a subsequent re-differentiation (MET) at the distant site is necessary to allow colonization and macrometastasis[14]. Intriguingly, the EMT-inducer Prrx1 suppresses stemness traits[15] and a knockdown of Prrx1 and TWIST1 increased lung metastasis after tail vein injection.

The question of whether the MET is stable in the metastases or if these cells show ongoing phenotypic plasticity leading to a second EMT is also an open question. Collectively, these results illustrate the plasticity governing self-renewal and mesenchymal gene interactions (Figure 1).

**INVOLVEMENT OF DICER IN EMT**

Genes central to gene regulatory networks (GRNs) may have a huge impact on cell plasticity. The ribonuclease type III endonuclease Dicer, involved in the RNA interference process, belongs to this gene category.RNA interference (RNAi) and microRNA (miRNA) pathways are conserved, post-transcriptional gene silencing mechanisms in which single-stranded guide RNAs bind to cognate mRNAs and direct their endonucleolytic cleavage or translational repression by RNA-induced silencing complexes (RISCs). An important function of Dicer is to process miRNA precursors into approximately 22-nucleotide non-coding small RNAs. As a master regulator of miRNA biogenesis, Dicer is involved in EMT, cancer cell plasticity and tumor progression. We have found that Dicer mRNA expression was variable in breast carcinoma samples and that lower levels were more frequent in patients with metastatic relapse, indicating that Dicer mRNA levels are clinically relevant as reported by Grelier *et al*[16]. In accordance with other studies, we have found a global decrease of miRNA expression in correlation with the decrease of Dicer expression[17]. Levels of Dicer are tightly controlled to maintain the homeostasis of miRNA production, largely at the post-transcriptional level. Dicer is a highly conserved protein that is found in almost all eukaryotic organisms. Some organisms contain multiple *Dicer* homologues, whereby different Dicer isotypes have distinct roles, for instance *D. melanogaster* Dicer-1 is required for miRNA biogenesis, whereas Dicer-2 functions in siRNA production. Contrary to other organisms, mammals have a single *Dicer* gene, but its expression is a highly regulated process with spliced Dicer mRNAs putatively encoding both spliced and full-length proteins. In humans, there are 3 full-length isoforms showing considerable differences in their 3’UTR sequence. Only two variants exhibit a long 3’UTR sequence, while the third variant exhibits a very short 3’UTR lacking all predicted miRNA target sites[18,19]. Moreover, we identified two splice variants which were highly expressed in some breast cancer cell lines, yet totally absent in others. Theoretically, these isoforms may be functional as they both contain the ribonuclease III domain and the dsRNA binding domain, while one isoform contains only a PAZ domain[18]. We have shown that the full-length Dicer protein decreased during the EMT process[16]. The presence of spliced forms was correlated with epithelial/mesenchymal phenotype. Indeed, in almost all cell lines that exhibit a complete or partial mesenchymal phenotype, these truncated isoforms were not detectable by western blot as shown by Hinkal *et al*[18]. Conversely, epithelial cells expressed easily-detectable levels of the two variants. Furthermore, we have found decreased expression of these variants during EMT using immortalized human epithelial mammary cells transfected by RAS. These data imply an integral role for internal site miRNA regulation of Dicer isoforms, but the physiological relevance of these data remains to be clarified. Thomas Duchaine’s group has shown the presence of a truncated form of Dicer in *C. elegans*, corresponding to a C-terminal fragment (sDCR-1). They demonstrated that sDCR-1 operates independently of full-length Dicer in two distinct RNAi pathways; it enhances exogenous RNAi (exoRNAi) and concurrently acts as a negative regulator of microRNA (miRNA) biogenesis[20]. Interestingly, one of the spliced form variants we identified in epithelial breast cancer cell lines encodes a protein sharing the same domains as sDCR-1. By ectopically expressing this isoform in HEK293T cells, they have found that, similar to the function of sDCR-1, there was a decrease in accumulation of mature-to-precursor forms for some miRNA but not all, showing that this function is miRNA-specific[20]. Deciphering the role of the highly conserved Dicer variants is of great importance since Dicer acts as a tumor suppressor in specific cancers[16,21,22]. As an miRNA target, full-length Dicer was also shown to be directly repressed by miR-103/107 and this repression enhanced breast cancer metastasis[23], whereas transcriptional induction of Dicer by Tap63 suppressed metastasis[24].

The nearly global decrease in miRNAs observed across a range of human tumors suggests that Dicer loss could be necessary for tumor progression. To better understand how cancer cells respond to loss of miRNA expression, Philip Sharp and collaborators[25] have characterized the effects of homozygous deletions of *Dicer1*-conditional alleles on the tumorigenicity of murine sarcoma cells and on the cellular phenotype of immortalized murine mesenchymal stem cells (MSCs). *Dicer1*-/- cells survived and proliferated without recovery of miRNA processing. Interestingly, their two models are mesenchymal, corroborating our results that show a repression of Dicer during the EMT process. Inactivation of p53, a common feature in both the sarcoma and MSC models, may facilitate, or be indispensable for, viability in the absence of Dicer. p53 loss was shown to allow primary MEFs to bypass an immediate senescence phenotype induced by *Dicer1* loss[26].

**MIRNAS AND BREAST CANCER PLASTICITY**

As a consequence of Dicer loss, tumors of epithelial origin should express more miRNAs than mesenchymal tumors. If we compare development and cancer progression, a parallel can be drawn between miRNA biogenesis during embryogenesis with repression of miRNAs synthesis in stem cells, and global miRNA loss during acquisition of cancer cell stemness. In embryonic zebrafish development, most miRNAs were expressed in a highly tissue-specific manner during segmentation and later stages, but not early in development. This suggests that they do not play a role in tissue fate establishment, but rather in differentiation or maintenance of tissue identity[27]. The link between deregulated miRNA expression and cancer has been well established, with miRNA profiling studies revealing distinct expression profiles in various cancers that could aid in the diagnosis of these malignancies[28-30]. Only a small subset of specific oncogenic miRNAs has been found to be upregulated in cancer.

Different miRNA signatures have been identified in the different breast cancer subtypes. Do these signatures reflect cell lineage of origin? miRNAs have been implicated in the development of murine mammary gland, which showed seven distinct temporal clusters during mammopoiesis[10] Among them, miRNAs clusters over-expressed during puberty and gestation in normal tissue of mammary gland, for example the miR-17–92 cluster, have been shown to play a crucial role in breast cell proliferation and have also been found in aggressive cancers, such as the basal-like subtype[32]. As has been found for other types of cancer, miR-21 appeared to predominantly act as an oncogene and its expression is inversely correlated with the tumor suppressor PTEN (Phosphatase and TENsin homolog) expression[33]. Another potent miRNA oncogene, miR-191 was positively regulated by estrogen and was shown to promote proliferation and invasion[34] miR-155 was also categorized as an oncomiR, as it was implicated in TGF-induced EMT, cell migration and invasion. Let-7 was the diametric opposite of miR-21, acting as a general tumor suppressor, and was found down-regulated in breast cancers. Let-7 has been described as a regulator of self-renewal and a pro-differentiation miRNA of breast cancer cells repressed by the Wnt–-catenin pathway[35], targeting oncogenes including RAS, HMGA2 and MYC. miR-21, miR-155 and let-7 are involved early in tumorigenesis and were found deregulated in benign breast tumors[36]. In contrast to miR-191, miR-206 was negatively regulated by estrogens and decreased miR-206 levels are associated with breast cancer of advanced clinical stage and shorter overall survival. Different studies have profiled the expression of miRNAs as a function of intrinsic breast cancer subtype. A clear miRNAs signature was identified in luminal breast cancer, with over-expression of miR-191 and miR-26 and down-regulation of miR-206. Interestingly, based on miRNAs signatures, the tumors can be easily classified as luminal A, luminal B, normal-like, HER2+ and basal-like[32].

EMT-TFs signatures were more often found in Triple Negative Breast cancer (TNBC), a very aggressive cancer subtype representing, however, a very heterogeneous group of breast cancers with the only common phenotype being ER-, PR- and HER2-negative. Further transcriptomic studies allowed the sub-classification of TNBC by identifying additional entities such as the Claudin-low subtype, characterized by low expression of claudin proteins, proliferation genes and luminal markers, and high expression of EMT markers and CSC-like features[37]. Interestingly, as previously mentioned for epithelial-mesenchymal dichotomy miRNA expression, the highly undifferentiated nature of TNBC is correlated with a global down-regulation of microRNAs[38]. However some miRNA are readily expressed in stem cells, such as the miR-302 cluster, “stemness miRNA cluster,” in ES cells which decreases upon cell differentiation, and is undetectable in somatic cells. An Oct4/Sox2-miR-302-cyclin D1 regulatory network governing ES cell pluripotency and self-renewal properties has been proposed[39]. miR-302 over-expression converts cancer cells into ES-like pluripotent stem cells associated with high expression of Oct3/4, SSEA-3, SSEA-4, Sox2, and Nanog[40]. The group of Carlos Caldas also identified miR-301a as a hub of pluripotency in breast cancers, and demonstrated that mRNA relationships altered in miR-301a high/low tumors showed a link between immune and EMT pathways, illustrated by the immunoglobulin superfamily member ALCAM, the EMT-TF ZEB2 and Claudin-3. miR-301a directly targeted and suppressed the tumor suppressor PTEN, one negative regulator of the Wnt/β-catenin signaling cascade, which promotes breast cancer invasion and metastasis. In the Claudin-low subtype, while the global decreased miRNAs expression can be assigned to a repression of Dicer expression, the down-regulation of miRNAs targeting transcription factors implicated in EMT and cancer stem cells may result from a transcriptional repression of their promoters. The miRNAs targets can directly drive this repression (Figure 2).

**FEEDBACK LOOPS INVOLVING MIRNAS DURING EMT-MET**

EMT is driven both by transcriptional and post-transcriptional changes. Because of the reversible nature of EMT, miRNAs functioning as co-repressors or co-activators are key players in this plasticity, specifically involved in regulation networks with EMT-TFs. miRNAs are categorized as either EMT-inducers or EMT-repressors, inversely involved in MET.

***miRNAs with EMT inducer activities***

The well-known oncomiR miR-21 was identified as an EMT-inducer, similarly to miR-103/107 which represses Dicer and PTEN expression during breast tumor initiation. PTEN is a major miR-21 target that negatively regulates EMT and CSC phenotypes. miR-10b was also identified as a positive regulator of EMT as it was demonstrated to be a positive effector of TWIST. It was shown to induce migration and invasion capacities in breast cancer cells via the direct targeting of the HOXD10 transcript. HOXD10 is a known repressor of genes involved in cell migration and extracellular matrix remodeling, including RHOC, α3 integrin, matrix metalloproteinase-14 and urokinase-type plasminogen activator receptor[41].

The oncomiR miR-206 expressed in aggressive breast tumors is involved in a double-negative feedback loop with ERand participates in EGFR-mediated abrogation of estrogenic responses in MCF-7 cells, thus contributing to a Luminal-A- to Basal-like phenotypic switch[54]. ER is also involved in a simple negative feedback with the miR-18a (17-92 cluster), where ER induced the expression of the mir-17-92 which in turn targets ERwith miR-18amir-17-92, an miRNA polycistron also known as oncomir-1, is among the most potent oncogenic miRNAs. Genomic amplification and elevated expression of mir-17-92 was found in several types of tumor, including mammary. mir-17-92 carries out pleiotropic functions during both normal development and malignant transformation, as it acts to promote proliferation, inhibit differentiation, increase angiogenesis, and sustain cell survival[55]. ER functions in a forward positive feedback loop with miR-375. Inhibiting miR-375 in ERα-positive MCF-7 cells resulted in reduced ERα activation and cell proliferation. Researchers have identified RASD1 (Dexamethasone-induced Ras-related protein 1), a small G protein of the Ras family, as a potential miR-375 target. Mechanistic investigations revealed that miR-375 regulates RASD1 by targeting the RASD1 3'UTR and RASD1 negatively regulates ERα expression[56]. miR-206, which contributes to a Luminal-A- to Basal-like switch, targets KLF4 (Kruppel-like factor 4) a pivotal transcription factor that is associated with both tumor suppression and oncogenesis. In untransformed cells, KLF4 likely acts as a potent inhibitor of proliferation. Conversely, in transformed cells, KLF4 suppresses the expression of p53 by directly acting on its promoter; consistently, KLF4 depletion from breast cancer cells restores p53 levels and causes p53-dependent apoptosis[57]. To further complicate the function of KLF4, it was shown that a co-operative binding of KLF4 and p53 to the DNA binding sites of some p53 targets, contributes to p53 target selectivity[58]. miR-206 levels were KLF4-dependent in breast cancer cells, and a KLF4-miR-206 feedback pathway was identified that negatively regulates protein translation in normal cells and cancer cells[59]. Very recently, KLF4 was evoked in a feedback loop involving p21. The tumor suppressor p21 has been shown to regulate gene expression by functioning as a transcription co-repressor. Li and collaborators[50], have identified p21-regulated miRNAs, among them, the miR-200 family and the miR-183-96-182 cluster, that were down-regulated in p21-deficient cells.

***miRNAs with EMT repressor activities***

miR-200 family members were identified as the guardians of the epithelial phenotype in many types of cancers, including breast cancers[42-44]. The miR-200 family activates the Sec23a-mediated tumor cell secretome which leads to secretion of metastasis-suppressive proteins. Predictably, loss of miRNA-200a is frequently observed in breast cancers, especially tumors with high-grade histology, but this loss does not predict tumor recurrence or patient survival[45]. miR-200 family members (miR-200a, miR- 200b, miR-200c, miR-141 and miR-429) encoded from two clusters, directly target the mRNAs of the E-cadherin transcriptional repressors ZEB1 and ZEB2. Interestingly, Thomas Brabletz’ group and others[43,46] have shown that both promoter regions are repressed in mesenchymal cells by ZEB1 and ZEB2 through their binding to a conserved pair of ZEB-type E-box elements, located proximal to the transcription start site. These findings establish a double-negative feedback loop controlling ZEB1-ZEB2 and miR-200 family expression. During EMT induced by TGF-, miR200s are inhibited mainly by ZEB1[43]. The induction and maintenance of a stable mesenchymal phenotype requires the establishment of autocrine transforming growth factor-β (TGF-β) signaling to drive sustained ZEB expression. Prolonged autocrine TGF-β signaling induced reversible DNA methylation of the miR-200 loci, demonstrating the existence of an autocrine TGF-β/ZEB/miR-200 signaling network that regulates cancer cell plasticity[47]. But the activity of this miRNA family is a doubled edged sword during cancer progression, as it has been shown to promote MET through E-cadherin up-regulation, allowing migrating cancer cells to colonize distant tissues. Intriguing, the role of the miR-200 family during metastatic colonization can be partly elucidated by the oncogene c-Myb, which was shown to activate the expression of all five members of the miR-200 family. The transcriptional activation of miR-200 by c-Myb occurs through binding to myb binding sites located in the promoter regions of miR-200 genes on human chromosomes 1 and 12. Furthermore, when c-Myb and the transcriptional repressor ZEB1 are co-expressed, such as at the onset of EMT, the repression by ZEB1 prevails over the activation by c-Myb, and miR-200s are repressed. Researchers have also shown a positive correlation between the expression of c-Myb and miR-200 members in a dataset of breast cancer patients[48].

Interestingly, another EMT-TF, Slug (SNAI2, Snail2) is transcriptionally regulated by c-Myb and induces vimentin, fibronectin, and N-cadherin expression and membrane ruffling via actin polymerization, consistent with the acquisition of partial but not complete mesenchymal-like phenotype[49]. Both expression of c-myb and miR-200 members lead to simultaneous expression of vimentin, N and E-cadherin. These data support the concept that, during distinct phases of tumor progression, the role of the genes involved in the EMT process may change in relation to the expression of other regulators and to epigenetic changes. Are both mesenchymal and epithelial traits required for metastatic progression at distant sites? The complex relationship between miR-200 and ZEB during tumor progression was also investigated in a xenograft orthotopic model of breast cancer metastasis, where ectopic expression of members of the miR-200b/200c/429, but not the miR-141/200a, limits tumor cell invasion and metastasis. Despite modulation of the ZEB1-E-cadherin axis, restoration of ZEB1 in miR-200b-expressing cells was not sufficient to alter metastatic potential, suggesting that other targets contribute to this process[50].

Other feedback loops between EMT-TFs and miRNAs were identified during breast tumor progression. miR-183 and miR-96 repressed common targets, including Slug, ZEB1, and KLF4. Re-introduction of miR-200, miR-183 or miR-96 into p21-/- cells inhibited EMT, cell migration and invasion. p21 forms a complex with ZEB1 at the miR-183-96-182 cluster promoter to inhibit transcriptional repression of this cluster by ZEB1, suggesting a reciprocal feedback loop. ZEB1 and ZEB2 are also involved in a negative feedback loop with miR-205 through the E-boxmotifs present in the miR-205 promoter sequences[51]. During Snail-induced EMT in MCF7 breast cancer cells, miR-203 and miR-200 family members were repressed in a correlated manner. Importantly, miR-203 repressed endogenous Snail, forming a double negative miR-203/Snail feedback loop[52]. miR-203 is also able to target Slug (SNAI2). In parallel with the TGF/ZEB/miR-200 negative loop, TGF-induced Slug to promote EMT by repressing the miR-203 promoter to inhibit its transcription. SNAI2 and miR-203 thus form a double negative feedback loop. It was found that miR-203 was significantly down-regulated in highly metastatic breast cancer cells, and the restoration of miR-203 in these cells inhibited tumor cell invasion *in vitro* and lung metastatic colonization *in vivo* by repressing Slug[53].

The miR-34 family is one of the most studied tumor suppressor miRNAs and comprises miR-34a, miR-34b and miR-34c. miR-34 is implicated in the inhibition of EMT mediated by p53. It was reported that activation of p53 down-regulates the EMT-inducing transcription factor Snail via induction of the miR-34a/b/c genes. Suppression of miR-34a/b/c caused up-regulation of Snail and EMT markers, and enhanced migration and invasion.  Ectopic miR-34a induced MET and down-regulation of Snail. miR-34a also down-regulated Slug and ZEB1, as well as the stemness factors BMI1, CD44, CD133, OLFM4 and c-MYC. Conversely, the transcription factors Snail and ZEB1 bind to E-boxes in the miR-34a/b/c promoters, thereby repressing miR-34a/b/c expression. miR-34a prevents TGF-β-induced EMT, and the repression of miR-34 genes by Snail and related factors is part of the EMT program[60]. miR-34 and SNAIL represent a double-negative feedback loop controlling cellular plasticity, governed by p53.

***Transcription factors/miRNAs regulating networks***

What are the targets of miRNAs during EMT/MET and what is the mode of TF- miRNA co-operation during pluripotency reprogramming? Sass *et al*[61] demonstrated that miRNAs which target the same protein complexes are frequently co-expressed. They experimentally verified that the miR141-200c cluster simultaneously targets several protein components of the CtBP(C-Term binding proteins)/ZEB complex (CtBP are conserved transcriptional co-repressors), implying an efficient regulation of a protein complex by a cluster of miRNAs. There is also evidence of functional redundancy among miRNAs resulting, in part, from miRNAs existing in large families sharing common seed sequences that can be co-expressed in the same cell. Redundancy also occurs at the level of co-targeting, where multiple distinct miRNAs with different sequences commonly target a single transcript through non-overlapping sites[62]. The miRNA-regulated protein complexes are mainly involved in regulation of transcription and chromatin modification. Conversely, house-keeping functions, such as translational elongation, are under-represented, meaning that miRNAs are “regulators of regulators”[61].

An important goal is to elucidate how complex TFs/miRNAs networks evolve in cancer. TFs and miRNAs are the two largest families of trans-acting, gene regulatory molecules in multicellular organisms, and they share a common regulatory logic. TFs generally do not work in isolation, but instead, together with co-regulators, they form large networks of co-operating and interacting transcription factors. The term “motif” was used to describe a small group that illustrates the regulation patterns of an miRNA, a TF, and their target genes. Common motifs, such as feedforward loops (FFLs) and feedback loops (FBLs) have been found to play crucial roles in cancer, such as the miR-17 cluster, E2F1, and c-Myc that modulate cellular proliferation[63]. However, the miRNA-TF synergistic effect may not be limited only to the FFLs or FBLs. Non-loop forms, such as the cascaded form, which have helped in understanding the regulatory mechanism, are also candidates[50]. miRNAs can also antagonize the function of other miRNAs, for example, miR-22 can suppress the expression of miR-200 via direct targeting of chromatin remodeling enzymes such as TET family members, which leads to the hypermethylation of the mir-200 promoter[64].

How can we decipher miRNA-regulating networks composed of proteins with opposite functions? For example, let-7 acts as a protective miRNA that inhibits RAS and transcriptional factors thus leading to cell commitment during development, but paradoxically Dicer, the master regulator of miRNA maturation is a hub for let-7 targeting. A recent finding may help us to understand this paradox; *ZEB2* transcript was shown to function as a competi­tive endogeneous RNA (ceRNA) for PTEN miRNAs. ZEB2 loss during MET can lead to repression of PTEN[65] and this regulation, that may appear counterintuitive at first glance, may explain how MET could be intricately linked to stemness acquisition (Figure 3).

**EMT, MIRNAS AND CHEMORESISTANCE**

Chemotherapeutics and radiotherapy effectively reduce tumor bulk but have little effect on cancer stem cells (CSC) that stimulate tumor recurrence, emphasizing the importance of identifying CSC-specific pathways that may be exploited to selectively target these resistant cells. Induction of EMT can activate some CSC state–specific signaling transcriptomic networks and the therapeutic resistance associatedwith CSCs. It was shown that EMT could be induced by chemotherapeutic agents and patients receiving neo-adjuvant therapy were more likely to express EMT-TFs in their circulating tumor cells (CTCs)[66]. Adriamycin treatment has been seen to induce EMT in a Twist-dependent manner in breast cancer cells. Additionally, irradiation, a common treatment modality in breast cancer, can increase EMT and CSC characteristics[67]. Tam and colleagues[68] found that EMT stimulated a switch between two main kinase pathways, through the protein kinase C (PKC). PKCwas activated following EMT by a shift from EGF receptor (EGFR) signaling, which predominated in non-CSCs, to autocrine platelet-derived growth factor receptor (PDGFR) signaling in mesenchymal stem-like cells and basal breast cancer cell lines. Up-regulation of PKCresulted in induction of the transcription factor FRA1 (FOS-like antigen 1), which was required for CSC viability and FRA1 expression was directly induced by the EMT transcription factors TWIST and Snail in triple-negative breast cancer (TNBC).

The mechanism of action of miRNAs in drug-induced EMT remains mainly unknown. miR-21 up-regulation has been associated with taxol resistance in breast cancer cells[69] and suppression of the oncogenic miR-21 sensitizes cancer cells to chemotherapy. Results by Li and collaborators[70] reported that miR-448 is the most strongly down-regulated miRNA following chemotherapy. Suppression of miR-448 correlated with EMT induction in breast cancer *in vitro* and *in vivo*. miR-448 suppression induces increasing epidermal growth factor receptor (EGFR)-mediated TWIST1 expression, as well as nuclear factor κB (NF-κB) activation. The authors have also demonstrated that the adriamycin-activated NF-κB directly binds the miR-448 promoter, suppressing its expression, suggesting a positive feedback loop between NF-κB and miR-448. It was shown that the loss of miRNA-200c correlated with the acquired resistance of breast cancer cells to adriamycine[71]. In breast CSC,the Wnt–-catenin pathway suppresses mature let-7 miRNAs by up-regulating Lin28, a negative let-7 biogenesis regulator. Loss of function of Lin28 impairs Wnt–-catenin-pathway-mediated let-7 inhibition and breast cancer stem cell expansion; enforced expression of let-7 blocks the Wnt–catenin pathway-stimulated breast CSC phenotype. Another study has shown that Lin28 expression was dramatically increased in tumor tissues after neoadjuvant chemotherapy, in local relapse and in metastatic breast cancer tissues[72].

**CONCLUSION**

Due to their implication in tumor development and metastasis, miRNAs represent potential therapeutics tools. Several studies either inhibiting or re-introducing miRNAs involved in EMT and CSCs regulation, are currently ongoing. Cai and collaborators[35] have delivered a let-7a agomir into the pre-malignant mammary tissues of MMTV-wnt-1 mice and shown that it resulted in a complete rescue of the stem cell phenotype driven by the Wnt–catenin pathway. An interesting approach to neutralize miRNAs is to saturate them with target mRNAs. These artificial targets are called “miRNA sponges”, expressing an mRNA containing multiple tandem binding sites for an endogenous miRNA and thus prevent the association of the miRNA with its endogenous targets[73]. We can hypothesize that introducing a ZEB2 miRNA sponge transcript in metastatic breast cancer cells may lead to a de-repression of PTEN transcripts.

In order to better evaluate the TFs--miRNAs regulatory relationships during mammary cancer progression, the next step is to identify specific combinations of epithelial and mesenchymal TFs-miRNAs networks co-existing in metastatic and stem-like cells in breast cancers. It is crucial to discriminate between the aberrant dynamics of epithelial–mesenchymal transitions during tumorigenesis and normal programs of embryonic development and wound healing. Interestingly, a synthetic analysis has shown that a core regulatory unit composed of two highly interconnected modules, the miR-34/SNAIL and the miR-200/ZEB double negative feedback loops, participate in the regulation of stemness, genome stability, cell–cell communication, and cellular motility. The authors have shown that the miR-200/ZEB loop exhibits tristability (the existence of three distinct stable states: epithelial, hybrid and mesenchymal) and that the miR-34/Snail circuit exhibits monostability (existence of a single stable state)[74]. Regarding breast tumorigenesis, the miR-200/ZEB circuit is likely involved in cell plasticity and the miR-34/Snail in the stabilization of metastatic phenotype.

Manipulation of the EMT-TF-miRNAs feedforward and/or feedback loops may provide new therapeutic targets for breast cancers.

**ACKNOWLEDGEMENTS**

We are grateful to Sarah Kabani for her critical review, E. Ruiz is a recipient of the Agency for Cancer Research.

**REFERENCES**

1 **Wang Y**, Dong J, Li D, Lai L, Siwko S, Li Y, Liu M. Lgr4 regulates mammary gland development and stem cell activity through the pluripotency transcription factor Sox2. *Stem Cells* 2013; **31**: 1921-1931 [PMID: 23712846 DOI: 10.1002/stem.1438]

2 **Zvelebil M**, Oliemuller E, Gao Q, Wansbury O, Mackay A, Kendrick H, Smalley MJ, Reis-Filho JS, Howard BA. Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers. *Breast Cancer Res* 2013; **15**: R25 [PMID: 23506684]

3 **Brabletz T**, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. *Cells Tissues Organs* 2005; **179**: 56-65 [PMID: 15942193]

4 **Thiery JP**, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. *Cell* 2009; **139**: 871-890 [PMID: 19945376 DOI: 10.1016/j.cell.2009.11.007]

5 **Creighton CJ**, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. *Proc Natl Acad Sci U S A* 2009; **106**: 13820-13825 [PMID: 19666588 DOI: 10.1007/s10911-010-9173-1]

6 **Morel AP**, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. *PLoS One* 2008; **3**: e2888 [PMID: 18682804 DOI: 10.1371/journal.pone.0002888]

7 **Mani SA**, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008; **133**: 704-715 [PMID: 18485877 DOI: 10.1016/j.cell.2008.03.027]

8 **Morel AP**, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux-Shisheboran M, Treilleux I, Tissier A, Gras B, Pourchet J, Puisieux I, Browne GJ, Spicer DB, Lachuer J, Ansieau S, Puisieux A. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. *PLoS Genet* 2012; **8**: e1002723 [PMID: 22654675 DOI: 10.1371/journal.pgen.1002723]

9 **Floor S**, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. *Oncogene* 2011; **30**: 4609-4621 [PMID: 21643013 DOI: 10.1038/onc.2011.184]

10 **Tsuji T**, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, Hu GF. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. *Cancer Res* 2008; **68**: 10377-10386 [PMID: 19074907 DOI: 10.1158/0008-5472.CAN-08-1444]

11 **Korpal M**, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. *Nat Med* 2011; **17**: 1101-1108 [PMID: 21822286 DOI: 10.1038/nm.2401]

12 **Celià-Terrassa T**, Meca-Cortés O, Mateo F, de Paz AM, Rubio N, Arnal-Estapé A, Ell BJ, Bermudo R, Díaz A, Guerra-Rebollo M, Lozano JJ, Estarás C, Ulloa C, Álvarez-Simón D, Milà J, Vilella R, Paciucci R, Martínez-Balbás M, de Herreros AG, Gomis RR, Kang Y, Blanco J, Fernández PL, Thomson TM. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. *J Clin Invest* 2012; **122**: 1849-1868 [PMID: 22505459 DOI: 10.1172/JCI59218]

13 **Chui MH**. Insights into cancer metastasis from a clinicopathologic perspective: Epithelial-Mesenchymal Transition is not a necessary step. *Int J Cancer* 2013; **132**: 1487-1495 [PMID: 22833228 DOI: 10.1002/ijc.27745]

14 **Tsai JH**, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. *Cancer Cell* 2012; **22**: 725-736 [PMID: 23201165 DOI: 10.1016/j.ccr.2012.09.022]

15 **Ocaña OH**, Córcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. *Cancer Cell* 2012; **22**: 709-724 [PMID: 23201163 DOI: 10.1016/j.ccr.2012.10.012]

16 **Grelier G**, Voirin N, Ay AS, Cox DG, Chabaud S, Treilleux I, Léon-Goddard S, Rimokh R, Mikaelian I, Venoux C, Puisieux A, Lasset C, Moyret-Lalle C. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. *Br J Cancer* 2009; **101**: 673-683 [PMID: 19672267 DOI: 10.1038/sj.bjc.6605193]

17 **Merritt WM**, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. *N Engl J Med* 2008; **359**: 2641-2650 [PMID: 19092150 DOI: 10.1056/NEJMoa0803785]

18 **Hinkal GW**, Grelier G, Puisieux A, Moyret-Lalle C. Complexity in the regulation of Dicer expression: Dicer variant proteins are differentially expressed in epithelial and mesenchymal breast cancer cells and decreased during EMT. *Br J Cancer* 2011; **104**: 387-388 [PMID: 21119658 DOI: 10.1038/sj.bjc.6606022]

19 **Courtois-Cox S**, Moyret-Lalle C. Epithelial-Mesenchymal Transition and Metastasis: Role of Dicer Expression, Stem cells and cancer stem cells, 2012, vol. 6, Springer Ed

20 **Sawh AN**, Duchaine TF. A truncated form of dicer tilts the balance of RNA interference pathways. *Cell Rep* 2013; **4**: 454-463 [PMID: 23933256 DOI: 10.1016/j.celrep.2013.07.013]

21 **Karube Y**, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T, Takahashi T. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. *Cancer Sci* 2005; **96**: 111-115 [PMID: 15723655]

22 **Valastyan S**, Weinberg RA. Metastasis suppression: a role of the Dice(r). *Genome Biol* 2010; **11**: 141 [PMID: 21118581 DOI: 10.1016/j.cell.2011.09.024]

23 **Martello G**, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, Parenti AR, Daidone MG, Bicciato S, Piccolo S. A MicroRNA targeting dicer for metastasis control. *Cell* 2010; **141**: 1195-1207 [PMID: 20603000 DOI: 10.1016/j.cell.2010.05.017]

24 **Su X**, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. *Nature* 2010; **467**: 986-990 [PMID: 20962848 DOI: 10.1038/nature09459]

25 **Ravi A**, Gurtan AM, Kumar MS, Bhutkar A, Chin C, Lu V, Lees JA, Jacks T, Sharp PA. Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. *Cancer Cell* 2012; **21**: 848-855 [PMID: 22698408 DOI: 10.1016/j.ccr.2012.04.037]

26 **Mudhasani R**, Zhu Z, Hutvagner G, Eischen CM, Lyle S, Hall LL, Lawrence JB, Imbalzano AN, Jones SN. Loss of miRNA biogenesis induces p19Arf-p53 signaling and senescence in primary cells. *J Cell Biol* 2008; **181**: 1055-1063 [PMID: 18591425 DOI: 10.1083/jcb.200802105]

27 **Wienholds E**, Plasterk RH. MicroRNA function in animal development. *FEBS Lett* 2005; **579**: 5911-5922 [PMID: 16111679]

28 **Calin GA**, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci U S A* 2004; **101**: 2999-3004 [PMID: 14973191]

29 **Volinia S**, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci U S A* 2006; **103**: 2257-2261 [PMID: 16461460]

30 **Murakami Y**, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. *Oncogene* 2006; **25**: 2537-2545 [PMID: 16331254]

31 **Avril-Sassen S**, Goldstein LD, Stingl J, Blenkiron C, Le Quesne J, Spiteri I, Karagavriilidou K, Watson CJ, Tavaré S, Miska EA, Caldas C. Characterisation of microRNA expression in post-natal mouse mammary gland development. *BMC Genomics* 2009; **10**: 548 [PMID: 19930549 DOI: 10.1186/1471-2164-10-548]

32 **Serpico D**, Molino L, Di Cosimo S. microRNAs in breast cancer development and treatment. *Cancer Treat Rev* 2014; **40**: 595-604 [PMID: 24286642 DOI: 10.1016/j.ctrv.2013.11.002]

33 **Si ML**, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. *Oncogene* 2007; **26**: 2799-2803 [PMID: 17072344]

34 **Di Leva G**, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder H, Nuovo G, Li M, Iorio MV, Galasso M, Santhanam R, Marcucci G, Perrotti D, Powell KA, Bratasz A, Garofalo M, Nephew KP, Croce CM. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. *PLoS Genet* 2013; **9**: e1003311 [PMID: 23505378 DOI: 10.1371/journal.pgen.1003311]

35 **Cai WY**, Wei TZ, Luo QC, Wu QW, Liu QF, Yang M, Ye GD, Wu JF, Chen YY, Sun GB, Liu YJ, Zhao WX, Zhang ZM, Li BA. The Wnt-β-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. *J Cell Sci* 2013; **126**: 2877-2889 [PMID: 23613467 DOI: 10.1242/jcs.123810]

36 **Tahiri A**, Leivonen SK, Lüders T, Steinfeld I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Børresen-Dale AL, Perälä M, Bukholm IR, Kristensen VN. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. *Carcinogenesis* 2014; **35**: 76-85 [PMID: 24104550 DOI: 10.1093/carcin/bgt333]

37 **D'Ippolito E**, Iorio MV. MicroRNAs and triple negative breast cancer. *Int J Mol Sci* 2013; **14**: 22202-22220 [PMID: 24284394 DOI: 10.3390/ijms141122202]

38 **Dvinge H**, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, Chin SF, Provenzano E, Turashvili G, Green A, Ellis I, Aparicio S, Caldas C. The shaping and functional consequences of the microRNA landscape in breast cancer. *Nature* 2013; **497**: 378-382 [PMID: 23644459 DOI: 10.1038/nature12108]

39 **Card DA**, Hebbar PB, Li L, Trotter KW, Komatsu Y, Mishina Y, Archer TK. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. *Mol Cell Biol* 2008; **28**: 6426-6438 [PMID: 18710938 DOI: 10.1128/MCB.00359-08]

40 **Lin SL**, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT, Ying SY. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. *RNA* 2008; **14**: 2115-2124 [PMID: 18755840 DOI: 10.1261/rna.1162708]

41 **Harquail J**, Benzina S, Robichaud GA. MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. *Cancer Biomark* 2012; **11**: 269-280 [PMID: 23248185 DOI: 10.3233/CBM-120291]

42 **Korpal M**, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. *J Biol Chem* 2008; **283**: 14910-14914 [PMID: 18411277 DOI: 10.1074/jbc.C800074200]

43 **Burk U**, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. *EMBO Rep* 2008; **9**: 582-589 [PMID: 18483486 DOI: 10.1038/embor.2008.74]

44 **Wellner U**, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. *Nat Cell Biol* 2009; **11**: 1487-1495 [PMID: 19935649 DOI: 10.1038/ncb1998]

45 **Jang K**, Ahn H, Sim J, Han H, Abdul R, Paik SS, Chung MS, Jang SJ. Loss of microRNA-200a expression correlates with tumor progression in breast cancer. *Transl Res* 2014; **163**: 242-251 [PMID: 24280074 DOI: 10.1016/j.trsl.2013.11.005]

46 **Bracken CP**, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. *Cancer Res* 2008; **68**: 7846-7854 [PMID: 18829540 DOI: 10.1158/0008-5472.CAN-08-1942]

47 **Gregory PA**, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, Lindeman GJ, Shannon MF, Drew PA, Khew-Goodall Y, Goodall GJ. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. *Mol Biol Cell* 2011; **22**: 1686-1698 [PMID: 21411626 DOI: 10.1091/mbc.E11-02-0103]

48 **Pieraccioli M**, Imbastari F, Antonov A, Melino G, Raschellà G. Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation. *Cell Cycle* 2013; **12**: 2309-2320 [PMID: 24067373 DOI: 10.4161/cc.25405]

49 **Tanno B**, Sesti F, Cesi V, Bossi G, Ferrari-Amorotti G, Bussolari R, Tirindelli D, Calabretta B, Raschellà G. Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin. *J Biol Chem* 2010; **285**: 29434-29445 [PMID: 20622260 DOI: 10.1074/jbc.M109.089045]

50 **Li X**, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, Bert AG, Selth LA, Anderson RL, Goodall GJ, Gregory PA, Khew-Goodall Y. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. *Oncogene* 2013; : [PMID: 24037528 DOI: 10.1038/onc.2013.370]

51 **Gregory PA**, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nat Cell Biol* 2008; **10**: 593-601 [PMID: 18376396 DOI: 10.1038/ncb1722]

52 **Moes M**, Le Béchec A, Crespo I, Laurini C, Halavatyi A, Vetter G, Del Sol A, Friederich E. A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. *PLoS One* 2012; **7**: e35440 [PMID: 22514743 DOI: 10.1371/journal.pone.0035440]

53 **Ding X**, Park SI, McCauley LK, Wang CY. Signaling between transforming growth factor β (TGF-β) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. *J Biol Chem* 2013; **288**: 10241-10253 [PMID: 23447531 DOI: 10.1074/jbc.M112.443655]

54 **Adams BD**, Cowee DM, White BA. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. *Mol Endocrinol* 2009; **23**: 1215-1230 [PMID: 19423651 DOI: 10.1210/me.2009-0062]

55 **Olive V**, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. *Int J Biochem Cell Biol* 2010; **42**: 1348-1354 [PMID: 20227518 DOI: 10.1016/j.biocel.2010.03.004]

56 **de Souza Rocha Simonini P**, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Volinia S, Croce CM, Najmabadi H, Diederichs S, Sahin O, Mayer D, Lyko F, Hoheisel JD, Riazalhosseini Y. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. *Cancer Res* 2010; **70**: 9175-9184 [PMID: 20978187 DOI: 10.1158/0008-5472.CAN-10-1318]

57 **Rowland BD**, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. *Nat Cell Biol* 2005; **7**: 1074-1082 [PMID: 16244670]

58 **Brandt T**, Townsley FM, Teufel DP, Freund SM, Veprintsev DB. Molecular basis for modulation of the p53 target selectivity by KLF4. *PLoS One* 2012; **7**: e48252 [PMID: 23118962 DOI: 10.1371/journal.pone.0048252]

59 **Lin CC**, Liu LZ, Addison JB, Wonderlin WF, Ivanov AV, Ruppert JM. A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context. *Mol Cell Biol* 2011; **31**: 2513-2527 [PMID: 21518959 DOI: 10.1128/MCB.01189-10]

60 **Siemens H**, Jackstadt R, Hünten S, Kaller M, Menssen A, Götz U, Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. *Cell Cycle* 2011; **10**: 4256-4271 [PMID: 22134354 DOI: 10.4161/cc.10.24.18552]

61 **Sass S**, Dietmann S, Burk UC, Brabletz S, Lutter D, Kowarsch A, Mayer KF, Brabletz T, Ruepp A, Theis FJ, Wang Y. MicroRNAs coordinately regulate protein complexes. *BMC Syst Biol* 2011; **5**: 136 [PMID: 21867514 DOI: 10.1186/1752-0509-5-136]

62 **Subramanyam D**, Blelloch R. From microRNAs to targets: pathway discovery in cell fate transitions. *Curr Opin Genet Dev* 2011; **21**: 498-503 [PMID: 21636265 DOI: 10.1016/j.gde.2011.04.011]

63 **O'Donnell KA**, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. *Nature* 2005; **435**: 839-843 [PMID: 15944709]

64 **Song SJ**, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, Richardson AL, Pandolfi PP. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. *Cell* 2013; **154**: 311-324 [PMID: 23830207 DOI: 10.1016/j.cell.2013.06.026]

65 **Karreth FA**, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, Tuveson DA, Pandolfi PP. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. *Cell* 2011; **147**: 382-395 [PMID: 22000016 DOI: 10.1016/j.cell.2011.09.032]

66 **Mego M**, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. *Int J Cancer* 2012; **130**: 808-816 [PMID: 21387303 DOI: 10.1002/ijc.26037]

67 **Charpentier M**, Martin S. Interplay of Stem Cell Characteristics, EMT, and Microtentacles in Circulating Breast Tumor Cells. *Cancers (Basel)* 2013; **5**: 1545-1565 [PMID: 24240660 DOI: 10.3390/cancers5041545]

68 **Tam WL**, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, Wu ZJ, Krall JA, Bierie B, Guo W, Chen X, Liu XS, Brown M, Lim B, Weinberg RA. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. *Cancer Cell* 2013; **24**: 347-364 [PMID: 24029232 DOI: 10.1016/j.ccr.2013.08.005]

69 **Mei M**, Ren Y, Zhou X, Yuan XB, Han L, Wang GX, Jia Z, Pu PY, Kang CS, Yao Z. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. *Technol Cancer Res Treat* 2010; **9**: 77-86 [PMID: 20082533]

70 **Li QQ**, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, Wang WJ, Chen Q, Tang F, Liu XP, Xu ZD. Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. *Cell Death Differ* 2011; **18**: 16-25 [PMID: 20798686 DOI: 10.1038/cdd.2010.103]

71 **Chen Y**, Sun Y, Chen L, Xu X, Zhang X, Wang B, Min L, Liu W. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. *Mol Med Rep* 2013; **7**: 1579-1584 [PMID: 23546450 DOI: 10.3892/mmr.2013.1403]

72 **Lv K**, Liu L, Wang L, Yu J, Liu X, Cheng Y, Dong M, Teng R, Wu L, Fu P, Deng W, Hu W, Teng L. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. *PLoS One* 2012; **7**: e40008 [PMID: 22808086 DOI: 10.1371/journal.pone.0040008]

73 **Iorio MV**, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol Med* 2012; **4**: 143-159 [PMID: 22351564 DOI: 10.1007/978-1-62703-547-7\_14]

74 **Lu M**, Jolly MK, Levine H, Onuchic JN, Ben-Jacob E. MicroRNA-based regulation of epithelial-hybrid-mesenchymal fate determination. *Proc Natl Acad Sci U S A* 2013; **110**: 18144-18149 [PMID: 24154725 DOI: 10.1073/pnas.1318192110]

75 **Moreno-Bueno G**, Cubillo E, Sarrió D, Peinado H, Rodríguez-Pinilla SM, Villa S, Bolós V, Jordá M, Fabra A, Portillo F, Palacios J, Cano A. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. *Cancer Res* 2006; **66**: 9543-9556 [PMID: 17018611]

76 **Al Saleh S**, Sharaf LH, Luqmani YA. Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). *Int J Oncol* 2011; **38**: 1197-1217 [PMID: 21318221 DOI: 10.3892/ijo.2011.942]

77 **Hugo HJ**, Kokkinos MI, Blick T, Ackland ML, Thompson EW, Newgreen DF. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study. *Cells Tissues Organs* 2011; **193**: 23-40 [PMID: 21051859 DOI: 10.1159/000320174.PMID: ]

78 **Hollier BG**, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, Herschkowitz JI, Guerra R, Chang JT, Miura N, Rosen JM, Mani SA. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. *Cancer Res* 2013; **73**: 1981-1992 [PMID: 23378344 DOI: 10.1158/0008-5472]


79 **Apostolou P**, Toloudi M, Chatziioannou M, Ioannou E, Papasotiriou I. Cancer stem cells stemness transcription factors expression correlates with breast cancer disease stage. *Curr Stem Cell Res Ther* 2012; **7**: 415-419 [PMID: 23061814]

80 **Huang YH**, Luo MH, Ni YB, Tsang JY, Chan SK, Lui PC, Yu AM, Tan PH, Tse GM. Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases. *Histopathology* 2014; **64**: 494-503 [PMID: 24382260 DOI: 10.1111/his.12257]


81 **Blanchard AA**, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y. Claudin 1 expression in basal-like breast cancer is related to patient age. *BMC Cancer* 2013; **13**: 268 [PMID: 23721519 DOI: 10.1186/1471-2407-13-268]

82 **Ravindranath A**, Yuen HF, Chan KK, Grills C, Fennell DA, Lappin TR, El-Tanani M. Wnt-β-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. *Br J Cancer* 2011; **105**: 542-551 [PMID: 21772333 DOI: 10.1038/bjc.2011.269]


**P-Reviewers:** Dalay N, Nishiyama M, Scaggiante B **S-Editor:** Wen LL **L-Editor: E-Editor:**

****

**Figure 1 Epithelial to mesenchymal transition and mesenchymal to epithelial transition during breast tumor progression.** During tumor progression, cancer cells undergo an epithelial to mesenchymal transition (EMT) to acquire invasive, dissemination, chemoresistance and stem cell properties. Thus, an *in situ* carcinoma progresses to an invasive carcinoma and cells disseminate throughout the entire body *via* the blood and the lymphatic vessels. After dissemination, cells must undergo an mesenchymal to epithelial transition (MET) to colonize distant organs.



**Figure 2 Transcription factors and miRNA epithelial and mesenchymal expression networks in breast cancer.** Through activation of different signaling pathways such as TGF-β, Notch or Hyppo pathways and the down-regulation of Dicer, epithelial cells undergo the epithelial to mesenchymal transition. Transcription factors and miRNAs act together to be the “plastic surgeons” of the epithelial or mesenchymal phenotype. Regulation networks between these two main actors drive cells to plasticity.



**Figure 3 Feedback and feedforward loops existing between transcription factors and miRNA during breast cancer progression.** Epithelial and mesenchymal regulators modulate their own expression creating regulatory feedback and feedforward loops.

**Table 1** **Involvement of epithelial-mesenchymal transition-transcription factors in breast carcinogenesis**

|  |  |  |  |
| --- | --- | --- | --- |
| **EMT -TF** | **Transcription factor type** | **Deregulated in breast cancer** | **Association with biological and clinico-pathological features in breast cancer** |
| SNAI1 (Snail) | Zinc finger | High levels[75] | Lymph node metastasis, effusion, distant metastasis, recurrence |
| SNAI2 (Slug) | Zinc finger | High levels[76] | Effusion, distant metastasis, recurrence, stemness capacities |
| TWIST1 | Basic Helix-loop-Helix | Up-regulated[77] | Primary transformation, escape from failsafe programs, invasion, bone metastasis, angiogenesis, poor prognosis |
| ZEB1 | Zinc finger E-box-binding homeobox 1 | High levels[76; 77] | Invasion, distant metastasis |
| ZEB2 | Zinc finger E-box-binding homeobox 2 | High levels[76; 77] | Invasion, distant metastasis, stemness capacities |
| FoxC2 | forkhead-related protein FKHL14, FKH-14, mesenchyme fork head protein 1 | High levels[78] | Stemness capacities, distant metastasis |
| Oct3/4 | Octamer-binding transcription factor 4, POU domain, class 5, transcription factor 1S homeodomain transcription factor of the POU family | Up-regulated[79] | Stemness capacities, invasion, migration |
| Sox2 | Sex determining region Y-box 2 highly conserved DNA binding domains High-mobility group box domains | Up-regulated[80] | Tamoxifen-resistance, lymph node metastasis, stemness capacities |
| Prrx1 | Paired related homeobox 1 | High levels[15] | Metastasis, poor prognosis |
| TCF4 | Basic Helix-loop-Helix immunoglobulin transcription factor 2 | Up-regulated[81,82] | Metastasis, poorer prognosis in patients with high levels of osteopontin and better prognosis with low levels of osteopontin |

EMT-TF: Epithelial-mesenchymal transition-transcription factors.